A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

This 2 part study will evaluate the efficacy and safety of 12 and 24 weeks treatment with RO5190591 (danoprevir) in combination with Pegasys and Copegus, compared to Pegasys and Copegus alone, in treatment-naive patients with chronic hepatitis C genotype 1 virus infection.In Part 1 of the study, patients will be randomized to receive either 1) RO5190591 300mg po every 8 hours, 2) RO5190591 600mg po every 12 hours, 3) RO5190591 900mg po every 12 hours or 4) placebo, in combination with standard doses of Pegasys and Copegus. If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive either 1) RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours or 2)placebo, in combination with standard doses of Pegasys and Copegus. The anticipated time on study treatment is 24-48 weeks, and the target sample size is 100-500 individuals.

A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infectio

RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.

Drug: Copegus

1000 or 1200mg po daily for 24 or 48 weeks

Drug: Pegasys

180micrograms sc weekly for 24 or 48 weeks

Drug: RO5190591 (Danoprevir)

300mg po q8h for 12 weeks

Experimental: Part 1: RO5190591 600mg po

RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.

Drug: Copegus

1000 or 1200mg po daily for 24 or 48 weeks

Drug: Pegasys

180micrograms sc weekly for 24 or 48 weeks

Drug: RO5190591 (Danoprevir)

600mg po q12h for 12 weeks

Experimental: Part 1: RO5190591 900mg po

RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.

Drug: Copegus

1000 or 1200mg po daily for 24 or 48 weeks

Drug: Pegasys

180micrograms sc weekly for 24 or 48 weeks

Drug: RO5190591 (Danoprevir)

900mg po q12h for 12 weeks

Placebo Comparator: Part 2: Placebo

If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.

Drug: Copegus

1000 or 1200mg po daily for 24 or 48 weeks

Drug: Pegasys

180micrograms sc weekly for 24 or 48 weeks

Drug: Placebo

po for 24 weeks

Experimental: Part 2: RO5190591 300mg po

If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.